Sherlock Biosciences

Sherlock Biosciences

A synthetic biology company offering a medical diagnostics and engineering biology platform.

Sherlock Biosciences is a synthetic biology company offering a medical diagnostics and engineering biology platform that is headquartered in Cambridge, Massachusetts and was founded in 2019 by Feng Zhang, Jim Collins, David R. Walt, Rahul K. Dhanda, Omar Abudayyeh, Todd Golub, Jonathan Gootenberg, Deborah Hung, and Pardis Sabeti.

Products
SHERLOCK

SHERLOCK (Specific High sensitivity Enzymatic Reporter unLOCKing or INternal Splint-Pairing Expression Cassette Translation Reaction) is a CRISPR based technology for detecting unique genetic sequences of any DNA or RNA sequence from any organism or pathogen. SHERLOCK is made for the detection of single molecules part of nucleic acids targets by amplifying genetic sequences and programming CRISP to detect specific genetic sequences within each amplified sample, releasing a signal when a certain genetic sequence is detected.

INSPECTR

INSPECTR (Internal Splint-Pairing Expression Cassette Translation Reaction) is a synthetic biology platform that uses freeze-dried synthetically made gene networks as programmable molecular diagnostic devices. INSPECTR can be programmed to find targets differing by a single nucleotide without the need for scientific instruments and at room temperature. When INSPECTR finds a desired nucleic acid target is produces a reporter protein which can be detected as a diagnostic readout.

Coronavirus diagnostics

Sherlock Biosciences is developing a CRISPR-based diagnostic test for coronavirus after the outbreak of a new coronavirus strain, SARS-CoV-2 (2019-nCoV) that was declared a global emergency by the World Health Organization (WHO). The coronavirus strain has more recently been renamed SARS-CoV-2 with the disease called COVID-19 (coronavirus disease).

Funding
Sereis A

On April 23, 2019 Sherlock Biosciences completed their series A funding round with $49 million in funding from Northpond Ventures (lead investor), Baidu Ventures (lead investor), the Open Philanthropy Project, and other investors. the co-founder, president, and CEO of Sherlock Biosciences gave the following statement to reporters regarding the companies series A funding round:

Their support will be vital as we work to harness and direct the power of our SHERLOCK and INSPECTR platforms to develop rapid and more effective diagnostic tests through Engineering Biology and Deep Learning tools that can be performed anywhere, such as testing in the field or home.

Timeline

April 23, 2019
Sherlock Biosciences raises a $49,000,000 series A round.
April 23, 2019
Sherlock Biosciences raises a $31,000,000 series A round from Northpond Ventures.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Sherlock Biosciences Series A round, April 2019
31,000,000
April 23, 2019
2 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace Editorial Staff
June 8, 2020
BioSpace
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 8, 2020.
BioSpace
June 8, 2020
BioSpace
Sherlock Biosciences and Integrated DNA Technologies (IDT) today announced the companies have entered into a strategic collaboration to enable large-scale manufacturing of the SherlockTM CR
BioSpace Editorial Staff
May 8, 2020
BioSpace
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.
Amirah Al Idrus
May 7, 2020
FierceBiotech
The FDA granted its first emergency authorization for a CRISPR-based test for COVID-19, developed by Sherlock Biosciences, designed to turn results around in about an hour compared to the four to six hours needed for other molecular diagnostics.
Allison DeAngelis
May 7, 2020
AmericanInno
The FDA has authorized emergency use of a coronavirus test developed by Cambridge startup Sherlock Biosciences that incorporates the CRISPR gene-editing technology
Nicole Wetsman
May 7, 2020
The Verge
CRISPR technology can quickly find and lock onto genetic sequences, like the one in the coronavirus. The test from Sherlock Biosciences uses that system to identify the virus in a patient sample.
Cormac Sheridan
March 23, 2020
Scientific American
Scientific American is the essential guide to the most awe-inspiring advances in science and technology, explaining how they change our understanding of the world and shape our lives.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.